Skip to main content
MYGNMyriad Genetics, Inc.Sell4.4·$5.66
SellModerate Confidence
Investment thesis

Myriad Genetics is a shrinking, unprofitable diagnostics company whose stock has rallied well above the analyst target, with falling estimates and a likely earnings test in 3 days making the rally hard to defend.

Thesis pillars

  • Price Well Above Target↑Improving
  • Declining Revenue Weak Economics→Stable
  • Earnings Misses Ahead Of Report↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 1, 2026, based on the 10-K filed Feb 24, 2026

Full reasoning →

Open full analysis

Myriad Genetics, Inc. (MYGN) Stock Analysis

Range Bound setup

SellVALUE-TRAP 2/5ShortModerate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Engine safety override at $5.66: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 2.40; Below-average business quality; Negative price momentum.

Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk), companion diagnostics (BRACAnalysis CDx, MyChoice CDx), prostate and breast cancer prognostics (Prolaris, EndoPredict), prenatal screening (Prequel, Foresight,... Read more

$5.66-9.3% A.UpsideScore 4.4/10#28 of 32 Diagnostics & Research
QualityF-score4 / 9FCF yield0.93%
Stop $5.26Analyst target $5.13(reached)A.R:R -0.6:1
Analyst consensus$5.90+4.2%8 analysts with price targets
$5.66price
$5.90mean
$4
$8

Sell if holding. Engine safety override at $5.66: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 2.40; Below-average business quality; Negative price momentum. Chart setup: RSI 43 mid-range, Bollinger mid-band. Score 4.4/10, moderate confidence.

Passes 5/8 gates (clean insider activity, news boost analyst 0.40, earnings proximity 99d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Myriad Genetics, Inc.

About Myriad Genetics, Inc.

Myriad Genetics sells its MyRisk hereditary cancer test across eleven cancer types and BRACAnalysis CDx, the only FDA-approved germline BRCA companion diagnostic for breast cancer with additional approvals in ovarian, pancreatic and prostate cancer, alongside MyChoice CDx, an HRD companion diagnostic validated in more than 20,000 patients. The company invested $106.8 million in research and development during 2025, down from $113.4 million in 2024, as it advanced newer tests including Precise MRD for molecular residual disease monitoring and FirstGene, a combined prenatal screen in early-access clinical study. Myriad primarily sells through its own sales force in the United States and Japan, expanding into Europe and Asia-Pacific through indirect distribution channels.

Myriad organizes its testing menu around three franchises: Oncology, spanning hereditary cancer risk, companion diagnostics and molecular residual disease monitoring; Women's Health, covering prenatal screening and carrier testing; and Mental Health, anchored by the GeneSight pharmacogenomic test used to guide antidepressant and ADHD medication selection. The company competes against Natera, Foundation Medicine, Caris Life Sciences, Tempus, LabCorp, Quest Diagnostics, Veracyte, Guardant Health, MDxHealth and NeoGenomics across its oncology and diagnostics businesses, differentiating through its brand reputation in hereditary cancer testing and community-medicine commercial reach. In August 2024, Myriad divested its EndoPredict business to Eurobio Scientific while retaining rights to sell EndoPredict as a laboratory-developed test outside the European Union, and the company plans to discontinue U.S. EndoPredict sales during the first half of 2026 as it shifts focus toward the Cancer Care Continuum.

Show full overview

Myriad frames molecular residual disease testing, through its Precise MRD assay, as a significant new growth opportunity, but the test remains newly commercialized and competes in a market where Natera and Guardant Health already hold established MRD franchises with longer clinical track records. Because Myriad's community-medicine commercial reach is its stated competitive advantage for winning MRD share rather than a first-mover technology edge, the ultimate size of this opportunity depends on physician adoption patterns that the 10-K does not yet quantify with test-volume or revenue-contribution figures specific to Precise MRD.

See also: Healthcare · Diagnostics & Research

From Myriad Genetics, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 15, 2026

Recent Developments — Myriad Genetics, Inc.

Latest item Nov 15, 2026 · Generated 2026-11-16T12:07:47Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Feb 23, 202799d to earnings· next earnings call

Thesis

Rewards
Recent Analyst detected in news
Risks
Target reached (-9.3% upside)
Quality below floor (3.2 < 4.0)
Value-trap signals (2/5): High leverage (D/E 9.7), Material insider selling (17 sells, 0.14% of cap)

Key Metrics

P/E (TTM)—
P/E (Fwd)-9.1
Mkt Cap$543M
EV/EBITDA-11.3
Profit Mgn-16.1%
ROE-40.2%
Rev Growth-1.5%
Beta1.61
DividendNone
Analysts with ratings14

Quality Signals

Piotroski F4/9

Options Flow

P/C2.40bearish

Material Events(8-K, last 90d)

  • 2026-06-23Item 5.02LOW
    On June 17, 2026 director Daniel M. Skovronsky notified the Board of his resignation, effective immediately, not due to any disagreement with the company's operations, policies or practices. No successor named.
    SEC filing →
  • 2026-06-04Item 5.02LOW
    At Myriad Genetics' 2026 annual meeting, stockholders approved a 4,000,000-share increase to the Employee Stock Purchase Plan and a new 2026 Equity Incentive Plan reserving 8,463,567 shares. Routine equity-compensation plan approvals.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers

Revenue shrinking — -1.5% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
2.1
Declining revenue: -2%
Low model confidence on this dimension (33%).

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Macd
1.6
Ma Position
5.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-MA but MA slope flat

Unprofitable operations — net margin -16.1%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Rule Of 40
3.0
Fcf Quality
3.1
Piotroski F
4.4
Moat
4.8
Current Ratio
6.9
Gross Margin
9.7
FCF-positive despite GAAP loss (FCF margin 1%, FCF yield 0.9%)No competitive moatRule of 40: -1 (fail)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
1.0
Quality Rank
1.3
Value Rank
9.7
GatesMomentum 2.6<4.5A.R:R -0.6=NEGATIVEExecutive change: officer departure/appointmentInsider activity: OKNEWS BOOST ANALYST 0.40EARNINGS PROXIMITY 99d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
43 · Neutral
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $3.95Resistance $6.77

Price Targets

A.Upside-9.3%
A.R:R-0.6:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Target reached (-9.3% upside)
! Quality below floor (3.2 < 4.0)
! Value-trap signals (2/5): High leverage (D/E 9.7), Material insider selling (17 sells, 0.14% of cap)

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-02-23 (99d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is MYGN stock a buy right now?

Sell if holding. Engine safety override at $5.66: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 2.40; Below-average business quality; Negative price momentum. Chart setup: RSI 43 mid-range, Bollinger mid-band. Prior stop was $5.26. Score 4.4/10, moderate confidence.

What is the MYGN stock price target?

Analyst target $5.13 reached (−9.3% from $5.66); no take-profit level is published. Prior stop was $5.26. Stop-loss: $5.26.

What are the risks of investing in MYGN?

Target reached (-9.3% upside); Quality below floor (3.2 < 4.0); Value-trap signals (2/5): High leverage (D/E 9.7), Material insider selling (17 sells, 0.14% of cap).

Is MYGN overvalued or undervalued?

Myriad Genetics, Inc. trades at a P/E of N/A (forward -9.1). TrendMatrix value score: 6.4/10. Verdict: Sell.

What do analysts say about MYGN?

14 analysts rate MYGN, with a consensus score of 2.5/5. 8 analysts publish price targets averaging $6.

What does Myriad Genetics, Inc. do?Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk),...

Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk), companion diagnostics (BRACAnalysis CDx, MyChoice CDx), prostate and breast cancer prognostics (Prolaris, EndoPredict), prenatal screening (Prequel, Foresight, FirstGene, SneakPeek) and pharmacogenomic mental-health testing (GeneSight). The company sells these tests to providers and health systems primarily in the United States and Japan, competing against Natera, Foundation Medicine, Caris Life Sciences, Tempus, LabCorp and Quest Diagnostics. Myriad spent $106.8 million on research

Related stocks: VCYT (Veracyte, Inc.) · CDNA (CareDx, Inc.) · CSTL (Castle Biosciences, Inc.) · SHC (Sotera Health Company) · OPK (Opko Health, Inc.)
Home › Stocks › MYGN

Latest news

Latest News

Fiscal.ai22h agoAnalyst
Fiscal.ai3d ago
Benzinga4d agoAnalyst
Fiscal.ai10d agoAnalyst
Fiscal.ai11d ago
Benzinga11d agoAnalyst
Benzinga11d agoAnalyst
Benzinga11d ago
Fiscal.ai12d ago
Benzinga12d agoEarnings
Benzinga12d agoEarnings
Benzinga12d ago
Fiscal.ai14d ago
Fiscal.ai25d ago
Benzinga27d ago
Benzinga27d agoMerger Acquisition
Benzinga27d ago
Benzinga27d ago
Benzinga27d agoRestructuring
Benzinga39d ago